Germany Considers Tax Breaks for Pharma Companies Based on Investment

Germany's Ministry for Economic Affairs has proposed a new regulation, a "location clause," designed to incentivize pharmaceutical companies to invest in the country. Under this provision, companies that demonstrate significant investment in research, development, production, and employment in Germany could receive exemptions from an additional manufacturer's rebate applicable to patented medicines.

The proposal is part of a broader effort to bolster Germany's position as a key player in the pharmaceutical sector. The aim is for the regulation to take effect by January 2027. Without this change, the current 7% manufacturer's rebate is set to increase to 15.5% next year. The location clause offers a mechanism to mitigate this increase for companies meeting specific criteria tied to their German operations.

These criteria include requirements related to the proportion of clinical trials conducted, research and development expenditures, and production investments within Germany. Companies fulfilling all conditions, such as substantial investments and adherence to collective bargaining agreements, could potentially see the additional manufacturer's rebate fully waived. Projections estimate this could reduce costs for public health insurance systems by €750 million to €850 million annually.

Industry associations, like Pharma Deutschland, view the location clause as a positive step but emphasize that it is insufficient on its own. Improvements are also needed in the prerequisites for clinical research, faster approval processes, and a more robust medical technology strategy. Final approval of the regulation will require further parliamentary and governmental review, along with the resolution of potential EU legal matters.